Table 1 –
Patient Characteristics
| NCCN Risk Group** | ||||
|---|---|---|---|---|
| Patient Characteristics | Total | Low | Intermediate | High |
| Number of Patients | 53 | 2 | 29 | 22 |
| Median Age (years (range)) | 72 (56–83) | 70.5 (69–72) | 72 (56–80) | 72.5 (57–83) |
| PSA (ng/dl) (mean ± SD) | 9.3 ± 5.8 | 3.7 ± 1.3 | 8.2 ± 4.0 | 11.2 ± 7.2 |
| PSA range | 2.3–24.7 | 2.7–4.6 | 3.8–19.9 | 2.3–24.7 |
| T-Stage | ||||
| T1 | 41 | 2 | 25 | 14 |
| T2A | 7 | 0 | 2 | 5 |
| T2B-C | 5 | 0 | 2 | 3 |
| Gleason Score* | ||||
| 6 | 3 | 2 | 0 | 0 |
| 7 | 30 | 0 | 29 | 1 |
| 8+ | 20 | 0 | 0 | 21 |
| MRI prostate volume (cc) (mean ± SD) | 51.7 ± 21.7 | 63.0 ± 9.9 | 51.6 ± 21.7 | 50.9 ± 22.9 |
*
NCCN risk group and Gleason score categories based on highest overall Gleason score from systematic or targeted biopsy